Biopharma Sector Leadership in Transition

摘要

Despite intermittent pulses of IPO activity, the market for new bio-pharmaceutical issues has largely appeared anemic since the surge of activity in 2000. The 53 new issues to debut that year established a high-water mark that has not been approachedsince. The best year for new issues since 2000 was 2004, which saw the completion of 25 biopharmaceutical IPOs.